Congestive Heart Failure Drugs Market Size, Share, Global Analysis, Restrains, Segments, Competitive Players, Merger and Regional Outlook to 2026

SEATTLE, April 02, 2021, (PHARMIWEB) — Global Congestive Heart Failure Drugs Market

Congestive heart failure, commonly known as heart failure, is a medical condition that affects the pumping ability of the heart muscles. Certain medical conditions, such as narrowing of the heart’s arteries or high blood pressure, gradually weaken and stiffen the heart, preventing it from pumping efficiently. Some common symptoms of heart failure include shortness of breath; weakness; fatigue; swelling in legs, feet and ankles; irregular and rapid heartbeat; declined ability to exercise; persistent cough or wheezing with blood-tinged phlegm; frequent urination during the night; swollen abdomen; rapid weight gain due to fluid retention; lack of appetite; nausea; difficulty in concentration; decreased alertness; and foamy mucus. Therefore, the risk factors for this condition are high blood pressure, coronary artery disease, diabetes, sleep apnea, obesity, virus, alcohol intake, hypertension, and irregular heartbeat.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1839

There are four types of heart failure: left-sided heart failure, right-sided heart failure, systolic heart failure, and diastolic heart failure. Thus, various lifestyle changes can aid in the prevention of heart failure. By reducing and managing stress, maintaining a healthy body weight, eating healthy food, staying physically fit and active, controlling blood pressure and diabetes, one can keep oneself from such a fatal disease.

Global Congestive Heart Failure Drugs Market Dynamics

One of the most vital growth drivers for the global congestive heart failure drugs market is the robust pipeline of drugs currently under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University, in collaboration with Scpharmaceuticals Inc., had been going through the Phase 2 clinical trials in 2015. This injection is indicated for the treatment of heart failure. Moreover, Tolvaptan, which was sponsored by Otsuka Pharmaceuticals Co. Ltd., underwent the Phase 3 clinical trials in 2016. This drug is indicated for treating heart failure in children.

FDA approval of new drugs is another factor expected to fuel the growth of the global congestive heart failure drugs market. For instance, in 2016, the FDA approved Byvalson by Allergan, an Ireland-based company. This drug is used for treating hypertension. In 2015, the U.S. regulator approved Corlanor (ivabradine) by Amgen Inc., a U.S.-based company. This drug is used to treat chronic heart failure. Additionally, increasing geriatric population, unhealthy lifestyle, and surging awareness about various treatment options for chronic disorders, are driving the global market growth.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3rKLCwk

On the contrary, low awareness about the diagnosis of diseases, such as hypertension, acts as a major restraint for the global market growth. According to a 2013 study published in the NCBI, only 49% of patients in high-income countries, suffering from hypertension, were aware of diagnosis of the disease, and the percentage was even lower in several low-income countries.

Global Congestive Heart Failure Drugs Market – Regional Analysis

North America is expected to hold a dominant position in the global congestive heart failure drugs market, with upcoming new product launches and mergers & acquisitions. For instance, in 2015, Amgen Inc. a U.S.-based company acquired Dezima Pharma, a Netherlands based company to expand its cardiovascular drug portfolio by adding cholesterol lowering drug TA-8995 to its portfolio. TA-8995 is a cholesterol lowering drug. Moreover, Europe congestive heart failure drugs market is expected to witness significant growth due to launch of new drugs to treat chronic diseases, which prevent heart failures. For instance, Novartis AG launched a drug named Entresto in 2016, in UK. Entresto is used to treat heart failure with minimum ejection fraction (measurement of percentage of blood leaving heart each time it contracts), it is an angiotensin receptor-neprilysin inhibitor.

High prevalence of cardiovascular diseases in Asia Pacific is expected to support the growth of congestive heart failure drugs market in this region. According to a study conducted by the All India Institute of Medical Science (AIIMS) and Indian Council of Medical Research (ICMR) in 2016, India’s younger population, aged below 30 years, are at a higher risk of developing cardiovascular diseases, due to unhealthy lifestyles, high alcohol and tobacco consumption.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/congestive-heart-failure-drugs-market-1839

Global Congestive Heart Failure Drugs Market – Key Players

The leading players operating in the global congestive heart failure drugs market include Amgen Inc., Novartis AG, Astra Zeneca Plc., Bayer AG, Gilead Sciences Inc., Glaxo Smith Kline, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Market Taxonomy

By Drug:

• ACE Inhibitors
• Angiotensin 2 Receptor Blockers
• Beta Blockers
• Diuretics
• Aldosterone antagonists
• Inotropes
• Others

By Distribution Channel:

• Hospitals
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Europe
• Latin America
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837